Posted by Michael Wonder on 28 Apr 2021
Vertex announces European Commission approval for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat cystic fibrosis patients 12 years and older with at least one F508del mutation in the CFTR gene
28 April 2021 - New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type.
Vertex Pharmaceuticals today announced that the European Commission has granted approval of the label extension for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis in all patients ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
